Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine in Children With Autism
NCT04278898Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Feb 2021
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of acetylcysteine in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Stanford University. Primary endpoint: Change in glutamatergic neurometabolites at 1 hour. Started Feb 2021; status: recruiting.
02
Drugs
acetylcysteine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04278898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278898.